Orchestra BioMed Holdings Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a significant protocol update for the BACKBEAT global pivotal study, which evaluates AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension. This update expands patient eligibility criteria, now including hypertensive patients with Medtronic Azure™ or Astra™ dual-chamber pacemakers, significantly increasing the eligible patient pool by more than 24-fold compared to the original protocol. This expansion is expected to enhance the study's relevance and potential impact, aligning with the characteristics of the FDA Breakthrough Device Designation for AVIM therapy. The full implementation of the updated protocol is anticipated by the fourth quarter of 2025, supporting Orchestra BioMed's target to complete enrollment by mid-2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.